A Phase 3 interventional study of obudanersen in Angelman Syndrome, sponsored by Ionis Pharmaceuticals, Inc.. Recruiting at 1 site in United States. Open to participants aged 2 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.
Among the 33 studies in Angelman Syndrome with a site in United States, this one is the 18th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 in phase 3, and was the 33rd registered.
52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.
Browse Angelman Syndrome studies →6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 1+
OHB Pediatrics Ltd. · Sites in United States, Korea, Republic of, Taiwan
Ages 1–50
MavriX Bio, LLC · Sites in United States
Ages 4–50
Boston Children's Hospital · Sites in United States, Canada
RTI International · Sites in United States
Ages up to 99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.
This study: 2 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 9
First in 1999; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 66 across 29 interventional studies indexed under Angelman Syndrome.
Median enrollment 73 across the 24 interventional studies, 300 across the 9 observational. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 33 have an industry lead sponsor. The 10 most frequent:
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
Ionis Pharmaceuticals, Inc. has 3 studies filed under Angelman Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Angelman Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914609Phase 3Ionis Pharmaceuticals, Inc.REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | 2027-08 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Angelman Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to evaluate efficacy of obudanersen in participants with AS due to uniparental disomy or imprinting defects (UPD/ID) as measured through expressive communication.
This is a Phase 3, open-label, single treatment arm, multi-center study in participants with Angelman syndrome due to paternal uniparental disomy or imprinting defects. The study will consist of 4 periods: a screening period of up to 28 days, an approximate 60-week Treatment Evaluation Period, followed by 101 weeks of Long-Term Extension (LTE) period, and an 8-month Post-Treatment Follow-up Period. There will be two age-based Cohorts enrolled in this study: Cohort 1 (pediatric participants (aged 2 to \<18 years old)) and Cohort 2 (adult participants (aged 18 to ≤50 years old). More individuals will be enrolled in Cohort 1 than in Cohort 2.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Cohorts 1 and 2 will be administered obudanersen via intrathecal (IT) bolus injection every 12 weeks during the Treatment Evaluation and LTE periods.
Drug: obudanersen
ION582 will be administered by IT injection.
Also known as: ION582
Change From Baseline in Performance on the Expressive Communication Domain Raw Score Without Caregiver Input of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1
Time frame: Baseline and Week 52
Change From Baseline in Bayley-4: Cognition Scale Raw Score Without Caregiver Input
Time frame: Baseline and Week 52
Change From Baseline in Aberrant Behavior Checklist - Second Edition - Community Version (ABC-2-C): Hyperactivity
Time frame: Baseline and Week 52
Change From Baseline in (ABC-2-C): Irritability
Time frame: Baseline and Week 52
Change From Baseline in Vineland Adaptive Behavior Scale-3 (Vineland-3): Receptive Communication Domain Raw Score
Time frame: Baseline and Week 52
Change From Baseline in Vineland-3: Daily Living Skills, Personal Domain Raw Score
Time frame: Baseline and Week 52
Change From Baseline in (Bayley-4): Fine Motor Domain Raw Score Without Caregiver Input
Time frame: Baseline and Week 52
Change From Baseline in Observer-Reported Communication Ability (ORCA): Overall Emerging and Mastery T Score
Time frame: Baseline and Week 52
Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for May 2028, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obudanersen